Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population

Tait Shanafelt, MD, Neil E. Kay, Kari Rabe, Timothy Call, MD, Clive S. Zent, MD, Susan Schwager, Jose Leis, Diane F. Jelinek, PhD, Susan Slager, PhD, Curtis Hanson

Blood (2010) 116 (21): 700.

https://doi.org/10.1182/blood.V116.21.700.700

Published: 2010

Journal Articles

Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL

Tait Shanafelt, MD, Han Tun, MD, Curtis Hanson, Clive S. Zent, MD, Jose Leis, Timothy Call, MD, Betsy LaPlant, Deborah Bowen, Kristina Laumann, Diane F. Jelinek, PhD, Neil E. Kay

Blood (2010) 116 (21): 1379.

https://doi.org/10.1182/blood.V116.21.1379.1379

Published: 2010

Journal Articles

Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).

Jonathan Moreira, MD, Timothy Call, MD, Kari Rabe, Randy Wendt, Clive S. Zent, MD, Neil E. Kay, MD, Deborah Bowen, Jose Leis, MD, Susan Slager, PhD, Jon Wilson, MD, Tait Shanafelt, MD

Blood (2010) 116 (21): 4610.

https://doi.org/10.1182/blood.V116.21.4610.4610

Published: 2010

Journal Articles

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Blood (2010) 116 (21): 2443.

https://doi.org/10.1182/blood.V116.21.2443.2443

Published: 2010

Journal Articles

Vitamin D Insufficiency and Prognosis In Chronic Lymphocytic Leukemia (CLL)

Tait Shanafelt, MD, Matthew Drake, Matthew Mauer, Cristine Allmer, Kari Rabe, Susan Slager, PhD, George Weiner, MD, Timothy Call, MD, Brian Link, Clive S. Zent, MD, Neil E. Kay, Curtis Hanson, Thomas E. Witzig, MD, James Cerhan, MD, PhD

Blood (2010) 116 (21): 2408.

https://doi.org/10.1182/blood.V116.21.2408.2408

Published: 2010

Journal Articles

Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia

Matthew J Maurer, James Cerhan, MD, PhD, Jerry A Katzmann, PhD, Brian Link, Cristine Allmer, Clive S. Zent, MD, Timothy Call, MD, Kari Rabe, Curtis A. Hanson, MD, Neil E. Kay, Susan Slager, PhD, Thomas E. Witzig, MD, Tait Shanafelt, MD

Blood (2010) 116 (21): 2409.

https://doi.org/10.1182/blood.V116.21.2409.2409

Published: 2010

Journal Articles

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Neil E. Kay, Wenting Wu, John C. Byrd, MD, Brian Kabat, Diane F. Jelinek, PhD, Clive S. Zent, MD, Timothy Call, Thomas Lin, MD, PhD, Tait Shanafelt

Blood (2008) 112 (11): 43.

https://doi.org/10.1182/blood.V112.11.43.43

Published: 2008

Journal Articles

Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL

Mark C Lanasa, MD, PhD, Sallie D Allgood, MS, Susan L. Slager, PhD, Nicola Camp, PhD, Logan Spector, PhD, Laura Rassenti, PhD, Neil E. Kay, Jon P Gockerman, MD, Alicia Volkheimer, MS, Barbara K Goodman, PhD, Sara Strom, PhD, Timothy Call, MD, James Cerhan, MD, PhD, Jose F Leis, MD, PhD, Lynn Goldin, PhD, Gerald Marti, MD, PhD, J Brice Weinberg, MD, Neil Caporaso, MD, Marc C. Levesque, MD, PhD

Blood (2008) 112 (11): 3144.

https://doi.org/10.1182/blood.V112.11.3144.3144

Published: 2008

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Craig B. Reeder, MD, Michel K. Gornet, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD, PhD, Ivana N. Micallef, MD, Luis F. Porrata, MD, Patrick B. Johnston, MD, PhD, Matthew J. Maurer, MS, Betsy LaPlant, MS, Brian Kabat, MS, David J. Inwards, MD, Joseph P. Colgan, MD, Timothy Call, MD, Svetomir Markovic, MD, PhD, Clive S. Zent, MD, Steven R. Zeldenrust, MD, PhD, Han W. Tun, MD, Thomas E. Witzig, MD

Blood (2007) 110 (11): 121.

https://doi.org/10.1182/blood.V110.11.121.121

Published: 2007

Journal Articles

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil Kay, MD, Susan Geyer, PhD, Timothy Call, MD, Tait Shanafelt, MD, Clive Zent, MD, Diane Jelinek, PhD, Renee Tschumper, Nancy Bone, Gordon Dewald, PhD, Thomas Lin, PhD, Nyla Heerema, PhD, Laura Smith, Michael Grever, MD, John Byrd, MD

Blood (2006) 108 (11): 35.

https://doi.org/10.1182/blood.V108.11.35.35

Published: 2006

Journal Articles

Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).

Daniel L. Van Dyke, PhD, Kimberly Stockero, Stephanie Fink, Stephanie Smoley, Sarah Paternoster, Susan Schwager, Tait Shanafelt, MD, Clive Zent, MD, Timothy Call, MD, Neil Kay, MD, Gordon Dewald, PhD

Blood (2005) 106 (11): 3278.

https://doi.org/10.1182/blood.V106.11.3278.3278

Published: 2005

Journal Articles

Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).

Gordon W. Dewald, PhD, Stephanie Fink, Stephanie Smoley, Kimberly Stockero, Sarah Paternoster, Schwager Susan, Erik C. Thorland, PhD, Daniel L. Van Dyke, PhD, Tait Shanafelt, MD, Clive Zent, MD, Timothy Call, MD, Neil Kay, MD

Blood (2005) 106 (11): 3255.

https://doi.org/10.1182/blood.V106.11.3255.3255

Published: 2005

Journal Articles

Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).

Pankaj Malhotra, William J. Hogan, Mark R. Litzow, Michelle A. Elliott, Angela Dispenzieri, Timothy Call, Neil E. Kay, Clive Zent, Dennis A. Gastineau, Steven M. Ansell, Suzanne Hayman, Morie A. Gertz, Martha Q. Lacy, Luis F. Porrata, David J. Inwards, Ayalew Tefferi

Blood (2005) 106 (11): 5420.

https://doi.org/10.1182/blood.V106.11.5420.5420

Published: 2005

Journal Articles

Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms.

Anne J. Novak, PhD, Deanna M. Grote, Steven C. Ziesmer, Thomas E. Witzig, MD, Shanafelt Tait, MD, Timothy Call, MD, Neil E. Kay, MD, Diane F. Jelinek, PhD, James R. Cerhan, MD, PhD, Stephen M. Ansell, MD, PhD

Blood (2004) 104 (11): 964.

https://doi.org/10.1182/blood.V104.11.964.964

Published: 2004

Journal Articles

Clinical Significance of Homozygous D13S319 Deletion in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Stephanie Fink, Susan Geyer, Ph.D., Tait Shanafelt, M.D., Stephanie Smoley, Sarah Paternoster, Karin Giordano, Renee Tschumper, Diane Jelinkek, Ph.D., Nancy Bone, Brian Kabat, Timothy Call, M.D., Robert Phyliky, M.D., Neil Kay, M.D., Gordon Dewald, Ph.D

Blood (2004) 104 (11): 2799.

https://doi.org/10.1182/blood.V104.11.2799.2799

Published: 2004

NARROW

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population

Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL

Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Vitamin D Insufficiency and Prognosis In Chronic Lymphocytic Leukemia (CLL)

Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).

Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).

Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).

Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms.

Clinical Significance of Homozygous D13S319 Deletion in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only